demonstrated that plasma %p‐tau217 (i.e., the ratio of phosporylated‐tau217 to nonphosphorylated tau) exhibits clinical performance comparable to or superior to FDA‐approved CSF tests currently used in clinical practice for detecting AD pathology.79 Here, MAPT is linked to Alzheimer disease.